Location: Hamburg, Germany
Cell therapy programs increasingly stall not on the science, but on finding a manufacturing partner who can carry a cell line from development through GMP production without handing it between vendors at each stage. Cellistic will bring that discussion to the European Society of Gene and Cell Therapy's 33rd Annual Congress in Hamburg, October 27–30, 2026.
Wesley Tidball, Senior Director Business Development, and Suzanne Snellenberg, VP of Cell Line Development, will represent Cellistic on-site. Suzanne will focus her conversations on cell line development and CRISPR-based gene editing.
Cellistic's Pulse™ platform carries iPSC programs from cell line development through GMP master cell banking, with Cellistic Echo™ scaling differentiation and manufacturing behind it, one team end to end rather than separate vendors at each stage. Our Belgium-based GMP facility supports that path from process development through clinical and commercial cGMP manufacturing.
If you would like to meet with Wes or Suzanne in Hamburg, please reach out to arrange time.